



## A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mrs. RAKSHAYA

AGE/ GENDER : 74 YRS/FEMALE **PATIENT ID** : 1298102

**COLLECTED BY** REG. NO./LAB NO. : 122410290019

REFERRED BY **REGISTRATION DATE** : 29/Oct/2024 04:35 PM BARCODE NO. : 12505397 **COLLECTION DATE** : 29/Oct/2024 04:36PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 29/Oct/2024 08:30PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Biological Reference interval Test Name** 

# **HAEMATOLOGY HAEMOGLOBIN (HB)**

HAEMOGLOBIN (HB) 8.7<sup>L</sup> 12.0 - 16.0 gm/dL

by CALORIMETRIC **INTERPRETATION:-**

Hemoglobin is the protein molecule in red blood cells that carries oxygen from the lungs to the bodys tissues and returns carbon dioxide from the tissues back to the lungs.

A low hemoglobin level is referred to as ANEMIA or low red blood count.

ANEMIA (DECRESED HAEMOGLOBIN):

1) Loss of blood (traumatic injury, surgery, bleeding, colon cancer or stomach ulcer)

2) Nutritional deficiency (iron, vitamin B12, folate)

3) Bone marrow problems (replacement of bone marrow by cancer)

4) Suppression by red blood cell synthesis by chemotherapy drugs

5) Kidney failure

6) Abnormal hemoglobin structure (sickle cell anemia or thalassemia).

## POLYCYTHEMIA (INCREASED HAEMOGLOBIN):

- 1) People in higher altitudes (Physiological)
- 2) Smoking (Secondary Polycythemia)
- 3) Dehydration produces a falsely rise in hemoglobin due to increased haemoconcentration
- 4) Advanced lung disease (for example, emphysema)
- 5) Certain tumors
- 6) A disorder of the bone marrow known as polycythemia rubra vera,
- 7) Abuse of the drug erythropoetin (Epogen) by athletes for blood doping purposes (increasing the amount of oxygen available to the body by chemically raising the production of red blood cells).

NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





## A PIONEER DIAGNOSTIC CENTRE

**NAME** : Mrs. RAKSHAYA

AGE/ GENDER : 74 YRS/FEMALE **PATIENT ID** : 1298102

**COLLECTED BY** REG. NO./LAB NO. : 122410290019

REFERRED BY **REGISTRATION DATE** : 29/Oct/2024 04:35 PM BARCODE NO. : 12505397 **COLLECTION DATE** : 29/Oct/2024 04:36PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 29/Oct/2024 08:30PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Biological Reference interval Test Name** 

### **GLYCOSYLATED HAEMOGLOBIN (HBA1C)**

6.1 % GLYCOSYLATED HAEMOGLOBIN (HbA1c): 4.0 - 6.4

WHOLE BLOOD

by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

mg/dL ESTIMATED AVERAGE PLASMA GLUCOSE 128.37 60.00 - 140.00 by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

**INTERPRETATION:** 

AS PER AMERICAN DIABETES ASSOCIATION (ADA):						
REFERENCE GROUP	GLYCOSYLATED HEMOGLOGIB (HBAIC) in %					
Non diabetic Adults >= 18 years	<5.7					
At Risk (Prediabetes)	5.7 <b>−</b> 6.4					
Diagnosing Diabetes	>= 6.5					
	Age > 19 Years					
	Goals of Therapy:	< 7.0				
Therapeutic goals for glycemic control	Actions Suggested:	>8.0				
	Age < 19 Years					
	Goal of therapy:	< 7.5				

### COMMENTS:

- 1. Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.
- 2. Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.
- 3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be 4.High

HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications

5. Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





## A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

**NAME** : Mrs. RAKSHAYA

**AGE/ GENDER** : 74 YRS/FEMALE **PATIENT ID** :1298102

**COLLECTED BY** REG. NO./LAB NO. : 122410290019

REFERRED BY **REGISTRATION DATE** : 29/Oct/2024 04:35 PM BARCODE NO. : 12505397 **COLLECTION DATE** : 29/Oct/2024 04:36PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 29/Oct/2024 08:30PM


**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Test Name Value** Unit **Biological Reference interval** 

### LIFOTRONIC Graph Report

Name:	Case:	Patient Type :	Test Date: 29/10/2024 20:08:03
Age:	Department:	Sample Type: Whole Blood EDTA	Sample ld: 12505397
Gender:			Total Area : 10060

Peak Name	Retention Time(s)	Absorbance	Area	Result (Area %)
HbA0	69	3164	8852	83.6
HbA1c	39	58	508	6.1
La1c	25	39	270	2.5
HbF	20	10	56	0.5
Hba1b	13	58	207	2.0
Hba1a	10	49	167	1.6





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



## A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

**NAME** : Mrs. RAKSHAYA

**AGE/ GENDER** : 74 YRS/FEMALE **PATIENT ID** : 1298102

**COLLECTED BY** REG. NO./LAB NO. : 122410290019

REFERRED BY **REGISTRATION DATE** : 29/Oct/2024 04:35 PM BARCODE NO. : 12505397 **COLLECTION DATE** : 29/Oct/2024 04:36PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 29/Oct/2024 11:04PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Test Name Value** Unit **Biological Reference interval** 

## **CLINICAL CHEMISTRY/BIOCHEMISTRY**

## **KIDNEY FUNCTION TEST (BASIC)**

UREA: SERUM by urease - glutamate dehydrogenase (gldh)	29.24	mg/dL	10.00 - 50.00
CREATININE: SERUM by ENZYMATIC, SPECTROPHOTOMETERY	1.23 <sup>H</sup>	mg/dL	0.40 - 1.20
BLOOD UREA NITROGEN (BUN): SERUM by CALCULATED, SPECTROPHOTOMETERY	13.66	mg/dL	7.0 - 25.0
BLOOD UREA NITROGEN (BUN)/CREATININE RATIO: SERUM by CALCULATED, SPECTROPHOTOMETERY	11.11 PKR	RATIO	10.0 - 20.0
UREA/CREATININE RATIO: SERUM by CALCULATED, SPECTROPHOTOMETERY	23.77	RATIO	
URIC ACID: SERUM by URICASE - OXIDASE PEROXIDASE	5.94	mg/dL	2.50 - 6.80
ADVICE	KINDLY CORRELATE CLINICALLY		



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



## A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mrs. RAKSHAYA

AGE/ GENDER : 74 YRS/FEMALE **PATIENT ID** : 1298102

**COLLECTED BY** REG. NO./LAB NO. : 122410290019

REFERRED BY **REGISTRATION DATE** : 29/Oct/2024 04:35 PM BARCODE NO. **COLLECTION DATE** : 29/Oct/2024 04:36PM : 12505397 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 29/Oct/2024 11:04PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Test Name Value** Unit **Biological Reference interval** 

**INTERPRETATION:** 

Normal range for a healthy person on normal diet: 12 - 20

To Differentiate between pre- and postrenal azotemia. INCREASED RATIO (>20:1) WITH NORMAL CREATININE:

1. Prerenal azotemia (BUN rises without increase in creatinine) e.g. heart failure, salt depletion, dehydration, blood loss) due to decreased glomerular filtration rate.

Ž.Catabolic states with increased tissue breakdown.

3.GI hemorrhage.

4. High protein intake.

5. Impaired renal function plus.

6. Excess protein intake or production or tissue breakdown (e.g. infection, GI bleeding, thyrotoxicosis, Cushings syndrome, high protein diet,

burns, surgery, cachexia, high fever)

7. Urine reabsorption (e.g. ureterocolostomy)
8. Reduced muscle mass (subnormal creatinine production)
9. Certain drugs (e.g. tetracycline, glucocorticoids)
INCREASED RATIO (>20:1) WITH ELEVATED CREATININE LEVELS:

1. Postrenal azotemia (BUN rises disproportionately more than creatinine) (e.g. obstructive uropathy).

2. Prerenal azotemia superimposed on renal disease.

### DECREASED RATIO (<10:1) WITH DECREASED BUN:

1.Acute tubular necrosis.

2.Low protein diet and starvation.

3. Severe liver disease.

4. Other causes of decreased urea synthesis.

5. Repeated dialysis (urea rather than creatinine diffuses out of extracellular fluid).

6.Inherited hyperammonemias (urea is virtually absent in blood)

7.SIADH (syndrome of inappropiate antidiuretic harmone) due to tubular secretion of urea.

8. Pregnancy

DECREASED RATIO (<10:1) WITH INCREASED CREATININE:

- 1. Phenacimide therapy (accelerates conversion of creatine to creatinine).
- 2. Rhabdomyolysis (releases muscle creatinine).
- 3. Muscular patients who develop renal failure

### **INAPPROPIATE RATIO**

1. Diabetic ketoacidosis (acetoacetate causes false increase in creatinine with certain methodologies, resulting in normal ratio when dehydration should produce an increased BUN/creatinine ratio).

2. Cephalosporin therapy (interferes with creatininé measurement).

\*\*\* End Of Report \*\*\*

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)